A start-up from Imperial College London is developing an implantable wireless sensor that monitors and treats cardiac failure.
Cardian’s pulmonary arterial pressure (PAP) sensor, which doesn’t require batteries or a power line, is read by an external portable device that’s the size of a smartphone and is worn on the body to provide continuous monitoring of pulmonary arterial pressure during daily activity.
Initially developed by Imperial College researchers Christopher McLeod, Mohammad Reza Bahmanyar and Longfang Zou — all co-founders of Cardian — the PAP sensor is designed to allow doctors to detect signals that escape current technologies, reducing hospitalizations and mortality.
Touchstone Innovation has invested £1.5 million (over $1.9M US) in Cardia to commercialize the technology, which amounts to a 53.7% interest in the start-up.
“This is a classic Imperial spin-out,” says Dani Bach, director of healthcare ventures at Touchstone Innovations. “The formation of Cardian capitalizes on more than a decade of research from Chris McLeod’s lab within the Department of Electrical and Electronic Engineering.
“We are assembling a strong management team to commercialize this compelling technology,” adds Bach. “Combined with the expertise of the founding academics, [this] gives us a great opportunity to help create a new company that could significantly impact the lives of millions of sufferers of cardiac failure.”